Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H29N5O4 |
| Molecular Weight | 439.5075 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=NC=C(C=C1)[C@H](CC(O)=O)N2CCN(CCCC3=NC4=C(CCCN4)C=C3)C2=O
InChI
InChIKey=HGFOOLONGOBCMP-IBGZPJMESA-N
InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1
| Molecular Formula | C23H29N5O4 |
| Molecular Weight | 439.5075 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:46:09 GMT 2025
by
admin
on
Mon Mar 31 23:46:09 GMT 2025
|
| Record UNII |
1JL033A2D0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
227963-15-7
Created by
admin on Mon Mar 31 23:46:09 GMT 2025 , Edited by admin on Mon Mar 31 23:46:09 GMT 2025
|
PRIMARY | |||
|
100000177670
Created by
admin on Mon Mar 31 23:46:09 GMT 2025 , Edited by admin on Mon Mar 31 23:46:09 GMT 2025
|
PRIMARY | |||
|
1JL033A2D0
Created by
admin on Mon Mar 31 23:46:09 GMT 2025 , Edited by admin on Mon Mar 31 23:46:09 GMT 2025
|
PRIMARY | |||
|
MK-0429
Created by
admin on Mon Mar 31 23:46:09 GMT 2025 , Edited by admin on Mon Mar 31 23:46:09 GMT 2025
|
PRIMARY | Description: MK-0429 is a potent and selective inhibitor of the .ALPHA.v.BETA.3 integrin, which showed therapeutic effects on bone turnover disease in men with hormone-refractory prostate cancer (HRPC) and bone metastases. MK-0429 was safe and efficacious in significantly decreasing melanoma metastasis in the lungs. MK-0429 may be useful for the prevention of metastatic melanoma. | ||
|
DTXSID901347137
Created by
admin on Mon Mar 31 23:46:09 GMT 2025 , Edited by admin on Mon Mar 31 23:46:09 GMT 2025
|
PRIMARY | |||
|
9853559
Created by
admin on Mon Mar 31 23:46:09 GMT 2025 , Edited by admin on Mon Mar 31 23:46:09 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The orally administered MK-0429 has completed a Phase I/II study in solid tumors with no reported safety issues [43]. However, no further development has been reported.
|
